Neurocrine Biosciences (NBIX) Deferred Taxes (2020 - 2026)

Neurocrine Biosciences has reported Deferred Taxes for 7 years, with the latest figure at -$61.1 million in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes fell 345.99% year-over-year to -$61.1 million; the trailing twelve-month figure through Mar 2026 stood at $118.0 million (up 197.36% YoY), and the FY2025 full-year result was $165.4 million, up 234.36% from the prior year.
• Deferred Taxes for Q1 2026 stood at -$61.1 million, down from $48.2 million in the prior quarter.
• The five-year high for Deferred Taxes was $168.3 million in Q3 2025, with the low at -$61.1 million in Q1 2026.
• Historically, Deferred Taxes has averaged -$3.3 million across 5 years, with a median of -$13.7 million in 2025.
• Annual changes were most pronounced in 2023 — Deferred Taxes tumbled 10433.33% — and 2025, when it soared 582.23%.
• Neurocrine Biosciences' Deferred Taxes stood at $13.5 million in 2022, then surged by 52.59% to $20.6 million in 2023, then plunged by 251.94% to -$31.3 million in 2024, then soared by 253.99% to $48.2 million in 2025, then tumbled by 226.76% to -$61.1 million in 2026.
• The last three Deferred Taxes figures came in at -$61.1 million (Q1 2026), $48.2 million (Q4 2025), and $168.3 million (Q3 2025), per Business Quant data.